Robert Nunan Associate Director, Advanced Modalities CAR T-Cells and the Dawn of Living Drugs Although CAR T-cell technology is 30 years old, understanding its efficacy as a cancer therapy is in its infancy Aug 29, 2018 | Robert Nunan A Fitness Model for Tumors Genomic mutations underlie uncontrolled cell growth but new research demonstrate how to turn these mutations into a tumor’s weakness Aug 16, 2018 | Robert Nunan Trying to Improve the Odds of Cancer Immunotherapy Checkpoint inhibitors have led to remarkable responses in a small percentage of patients. Could combining them with other drugs improve the odds? Jul 17, 2018 | Robert Nunan
CAR T-Cells and the Dawn of Living Drugs Although CAR T-cell technology is 30 years old, understanding its efficacy as a cancer therapy is in its infancy Aug 29, 2018 | Robert Nunan
A Fitness Model for Tumors Genomic mutations underlie uncontrolled cell growth but new research demonstrate how to turn these mutations into a tumor’s weakness Aug 16, 2018 | Robert Nunan
Trying to Improve the Odds of Cancer Immunotherapy Checkpoint inhibitors have led to remarkable responses in a small percentage of patients. Could combining them with other drugs improve the odds? Jul 17, 2018 | Robert Nunan
